drugset / Trial / NCT07211425

A Study in Healthy People to Test How Itraconazole Influences the Amount of BI 3031185 in the Blood

NCT07211425

Phase 1 Completed 14 enrolled Boehringer Ingelheim
NaCrossoverOpen-labelTreatment

Summary

The main objective of this trial is to investigate the effect of multiple oral doses of the strong CYP3A4 inhibitor itraconazole on the pharmacokinetics of a single dose of BI 3031185 following oral administration.

Timeline

Start
2025-10-08
Primary completion
2026-01-21
Completion
2026-01-21

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 3031185 Unknown Oral
Subject Itraconazole Small molecule Oral

Indications

No indication recorded.